Resumen
Ki-67, a protein found in actively growing and dividing cancer cells, serves as an important tumor biomarker in breast cancer. A higher Ki-67 level indicates faster cell multiplication. In this study, pathologists evaluated Ki-67 using two methods: a visual whole-slide assessment and a quantitative tumor margin analysis. The study was performed in early-stage breast cancer patients. The findings revealed that Ki-67 is a reliable method for guiding clinical decision-making. Notably, a cut-off value of 20% appeared most appropriate for prognosis estimation and prediction of therapy benefit in our cohort of patients.